Repository logo
  • English
  • Català
  • Čeština
  • Deutsch
  • Español
  • Français
  • Gàidhlig
  • Italiano
  • Latviešu
  • Magyar
  • Nederlands
  • Polski
  • Português
  • Português do Brasil
  • Srpski (lat)
  • Suomi
  • Svenska
  • Türkçe
  • Tiếng Việt
  • Қазақ
  • বাংলা
  • हिंदी
  • Ελληνικά
  • Српски
  • Yкраї́нська
  • Log In
    Have you forgotten your password?
Repository logoRepository logo
  • Communities & Collections
  • All Contents
  • English
  • Català
  • Čeština
  • Deutsch
  • Español
  • Français
  • Gàidhlig
  • Italiano
  • Latviešu
  • Magyar
  • Nederlands
  • Polski
  • Português
  • Português do Brasil
  • Srpski (lat)
  • Suomi
  • Svenska
  • Türkçe
  • Tiếng Việt
  • Қазақ
  • বাংলা
  • हिंदी
  • Ελληνικά
  • Српски
  • Yкраї́нська
  • Log In
    Have you forgotten your password?
  1. Home
  2. Browse by Author

Browsing by Author "Demirkan, F"

Now showing 1 - 8 of 8
Results Per Page
Sort Options
  • No Thumbnail Available
    Item
    Serum sickness-like reactions associated with type III insulin allergy responding to plasmapheresis
    Bayraktar, F; Akinci, B; Demirkan, F; Yener, S; Yesil, S; Kirmaz, C; Comlekci, A
  • No Thumbnail Available
    Item
    The Effect of FcγRIIIA Gene Polymorphism on the Treatment of Diffuse Large B-cell Non-Hodgkin Lymphoma: A Multicenter Prospective Observational Study
    Büyükkurt, N; Özcan, MA; Ergene, Ü; Payzin, B; Tunah, S; Demirkan, F; Özsan, H; Piskin, Ö; Ündar, B
    Objective: The curative treatment approach for diffuse large B-cell lymphoma (DLBCL) is controversial even in the rituximab (R) era. The aim of this study was to examine the Fc gamma RIIIA gene polymorphism distribution of DLBCL patients who had been treated with R-CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy. Furthermore, we investigated the impact of Fc gamma RIIIA gene polymorphism on the overall response rate (ORR) and overall survival (OS). Materials and Methods: Patients from 3 centers in the Aegean region of Turkey who had newly diagnosed CD20-positive DLBCL were enrolled in the study. The single nucleotide polymorphisms of the Fc gamma RIIIA gene were analyzed by real time-PCR. The response to treatment was determined in the middle and at the end of the protocol. During 2 years of follow-up, the patients were clinically and radiologically evaluated for disease status every 3 months. Results: Thirty-six patients were included in the study and the distributions of F/F, V/F, and V/V types of alleles of Fc gamma RIIIA were 25%, 50%, and 25%, respectively. Twenty-seven patients were considered as evaluable according to ORR and OS. The patients' ORR was 87.5%, 100%, and 50% in the F/F, V/F, and V/V allele groups, respectively. We did not establish any statistically significant differences among the 3 alleles groups in respect to ORR (p=0.93). The OS within 2 years in the F/F, V/F, and V/V allele groups was 62.5%, 100%, and 100%, respectively. The OS in the F/F allele group was found to be lower than in the other 2 allele groups (p=0.01). Conclusion: The distribution of gene polymorphisms in our study group was similar to those of previous studies. While ORR was similar between the groups, our results highlight a lower OS in F/F patients compared to other allele groups of Fc gamma RIIIA.
  • No Thumbnail Available
    Item
    Prospective registry of adult patients receiving therapeutic plasma exchange with a presumptive diagnosis of thrombotic microangiopathy (TMA): The Turkish hematology research and education group (ThREG)-TMA02 study
    Akpinar, S; Tekgunduz, E; Esen, R; Yilmaz, M; Karakus, V; Vural, F; Gediz, F; Aydogdu, I; Kaynar, L; Goker, H; Kelkitli, E; Ayyildiz, O; Demirkan, F
    To understand who uses social media and how often they do so, we examined the personality traits that predict frequency of using a set of 10 different types of social media (e.g., social networks, blogs, virtual worlds). Using survey data collected from two large-scale samples of young adults (Exploratory Study 1 N = 1586, Confirmatory Study 2 N =1432), we conducted direct replications of our findings to test whether the observed relationships between social media use and personality traits were reliable. Our replicated findings reveal that sex, age and extraversion are reliable predictors of several types of social media use (e.g., Facebook, Messaging Platforms, Online Forums), while other traits (e.g., agreeableness, Machiavellianism) showed unreliable associations. Our findings also reveal dimensions of multiplatform social media use that categorize the media ecologies of young adults and show significant associations with individual difference measures. (C) 2020 Published by Elsevier Inc.
  • No Thumbnail Available
    Item
    Prospective Real-World Outcomes of Acute Myeloid Leukemia
    Karakus, V; Iltar, U; Yenihayat, EM; Polat, MG; Celik, S; Malkan, UY; Seval, GC; Dogan, A; Akdeniz, A; Pinar, IE; Ozdalci, D; Ince, I; Erdem, R; Mehtap, O; Kirkizlar, HO; Kacmaz, M; Deveci, B; Aykas, F; Akat, GK; Kaya, SY; Ozturk, HBA; Sevindik, O; Can, F; Cekdemir, D; Aslan, C; Bulbul, H; Guven, ZT; Maral, S; Durusoy, SS; Demirkan, F; Goker, H; Ozkalemkas, F; Keklik, M; Toprak, SK; Yucel, EE; Atas, U; Alacacioglu, I
  • No Thumbnail Available
    Item
    Acute Myeloid Leukemia in Elderly, Unfit Patients: Analysis of Turkish AML Prospective Registry Database, on Behalf of Acute Leukemia Working Group of Turkish Society of Hematology
    Urlu, SM; Seval, GC; Yücel, EE; Mehtap, O; Yenihayat, EM; Polat, MG; Malkan, UY; Ozbalci, D; Kaya, SY; Durusoy, SS; Akdeniz, A; Kirkizlar, O; Dogan, A; Pinar, IE; Kacmaz, M; Ozturk, HBA; Atas, U; Deveci, B; Akat, GK; Guven, ZT; Sevindik, OG; Demirkan, F; Alacacioglu, I; Karakus, V
  • No Thumbnail Available
    Item
    A Multicenter Experience of Thrombotic Microangiopathies in Turkey: The Turkish Hematology Research and Education Group (ThREG)-TMA01 Study
    Tekgunduz, E; Yilmaz, M; Erkurt, MA; Kiki, I; Kaya, AH; Kaynar, L; Alacacioglu, I; Cetin, G; Ozarslan, I; Kuku, I; Sincan, G; Salim, O; Namdaroglu, S; Karakus, A; Karakus, V; Pamuk, GE; Altuntas, F; Sari, HI; Ozet, G; Aydogdu, I; Okan, V; Kaya, E; Yildirim, R; Yildizhan, E; Ozgur, G; Ozcebe, OI; Payzin, B; Akpinar, S; Demirkan, F
  • No Thumbnail Available
    Item
    A multicenter experience of thrombotic microangiopathies in Turkey: The Turkish Hematology Research and Education Group (ThREG)-TMA01 study
    Tekgündüz, E; Yilmaz, M; Erkurt, MA; Kiki, I; Kaya, AH; Kaynar, L; Alacacioglu, I; Cetin, G; Ozarslan, I; Kuku, I; Sincan, G; Salim, O; Namdaroglu, S; Karakus, A; Karakus, V; Altuntas, F; Sari, I; Ozet, G; Aydogdu, I; Okan, V; Kaya, E; Yildirim, R; Yildizhan, E; Ozgur, G; Ozcebe, OI; Payzin, B; Akpinar, S; Demirkan, F
    Thrombotic microangiopathies (TMAs) are rare, but life-threatening disorders characterized by microangiopathic hemolytic anemia and thrombocytopenia (MAHAT) associated with multiorgan dysfunction as a result of microvascular thrombosis and tissue ischemia. The differentiation of the etiology is of utmost importance as the pathophysiological basis will dictate the choice of appropriate treatment. We retrospectively evaluated 154 (99 females and 55 males) patients who received therapeutic plasma exchange (TPE) due to a presumptive diagnosis of TMA, who had serum ADAMTSI3 activity/antiADAMTS13 antibody analysis at the time of hospital admission. The median age of the study cohort was 36 (14-84). 67 (43.5%), 32 (20.8%), 27 (17.5%) and 28 (18.2%) patients were diagnosed as thrombotic thrombocytopenic purpura (TTP), infection/complement-associated hemolytic uremic syndrome (IA/CAHUS), secondary TMA and TMA-not otherwise specified (TMA-NOS), respectively. Patients received a median of 18 (1-75) plasma volume exchanges for 14 (153) days. 81 (52.6%) patients received concomitant steroid therapy with TPE. Treatment responses could be evaluated in 137 patients. 90 patients (65.7%) achieved clinical remission following TPE, while 47 (34.3%) patients had non-responsive disease. 25 (18.2%) non-responsive patients died during follow-up. Our study present real-life data on the distribution and follow-up of patients with TMAs who were referred to therapeutic apheresis centers for the application of TPE. (C) 2018 Elsevier Ltd. All rights reserved.
  • No Thumbnail Available
    Item
    Current practice of autologous hematopoietic progenitor cell mobilization in adult patients with multiple myeloma and lymphoma: The results of a survey from Turkish hematology research and education group (ThREG)
    Tekgündüz, E; Demirkan, F; Vural, F; Göker, H; Özdogu, H; Kiki, I; Aydogdu, I; Kaynar, L; Erkurt, MA; Çagirgan, S; Besisik, S; Dagdas, S; Koca, E; Kadiköylu, G; Gündüz, E; Yilmaz, M; Beköz, H; Ural, AU; Bastürk, A; Arat, M; Albayrak, M; Öztürk, E; Akyol, A; Bolaman, AZ; Nevruz, O; Özkan, HA; Özgür, G; Altuntas, F
    Autologous hematopoietic cell transplantation (AHCT) is an established treatment option for adult patients presenting with multiple myeloma (MM), Hodgkin lymphoma (HL) and various subtypes of non-Hodgkin lymphoma (NHL) in upfront and/or relapsed/refractory disease settings. Although there are recently published consensus guidelines addressing critical issues regarding autologous hematopoietic progenitor cell mobilization (HPCM), mobilization strategies of transplant centers show high variability in terms of routine practice. In order to understand the current institutional policies regarding HPCM in Turkey and to obtain the required basic data for preparation of a national positional statement on this issue, Turkish Hematology Research and Education Group (ThREG) conducted a web-based HPCM survey. The survey was designed to include multiple-choice questions regarding institutional practice of HPCM in adults presenting MM, HL, and NHL. The representatives of 27 adult HCT centers participated to the study. Here we report the results of this survey shedding light on the real world experience in Turkey in terms of autologous HPCM mobilization strategies in patients presenting with MM and lymphoma. (C) 2017 Elsevier Ltd. All rights reserved.

Manisa Celal Bayar University copyright © 2002-2025 LYRASIS

  • Cookie settings
  • Privacy policy
  • End User Agreement
  • Send Feedback